<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90745">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912053</url>
  </required_header>
  <id_info>
    <org_study_id>2012-EB-CHOL-Th</org_study_id>
    <secondary_id>2012-001213-16</secondary_id>
    <secondary_id>A121007-71</secondary_id>
    <nct_id>NCT01912053</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma</brief_title>
  <acronym>MispheC</acronym>
  <official_title>An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <authority>France : ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and tolerance of intra-hepatic
      administration of Yttrium 90-labelled microsphere (Theraspheres®, Nordion) in association
      with intravenous chemotherapy with Gemcitabin and Cisplatin for the treatment of
      intra-hepatic cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Radiological response rate to the treatment with the association of chemotherapy and radioembolization</measure>
    <time_frame>3 months after radioembolization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation according RECIST 1.1 criteria. Rate will be reassessed every 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of intra-hepatic administration of Yttrium 90-labelled microspheres in association with intravenous chemotherapy with Gemcitabine and Cisplatin assessed according NCI/CTC AE version 4.</measure>
    <time_frame>Up to  24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Grade 3-4 toxicity appearance.Time between 1st treatment administration and date of 1st appearance of a grade 3-4 toxicity or date of last toxicities assessment in case no grade 3-4 toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor markers changes (CA19.9, CEA and AFP)</measure>
    <time_frame>Up to  24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Markers will be analysed every 8 weeks during treatment period and if applicable every 12 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rate by the CHOI criteria</measure>
    <time_frame>Up to  24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>every 8 weeks and every 12 weeks after surgery if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic activity measured by TEP</measure>
    <time_frame>Change from baseline in metabolic activity 15 and 24 weeks after last treatment by microspheres</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of liver volume</measure>
    <time_frame>Up to  24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Every 8 weeks during treatment and every 12 weeks after surgery if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral and non-tumoral dosimetric assessment of the liver</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data obtained from SPECT/CT performed at each hepatic scintigraphy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Therasphere®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therasphere® in association with Gemcitabine and Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Therasphere® in association with Gemcitabine and Cisplatin</intervention_name>
    <description>Therasphere® is a radioelement</description>
    <arm_group_label>Therasphere®</arm_group_label>
    <other_name>90-Yttrium theraspheres</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed intra-hepatic cholangiocarcinoma.

          2. Measurable target of at least 2 cm diameter.

          3. Healthy liver or cirrhosis CHILD &lt; B8.

          4. WHO-PS: 0-1.

          5. Age ≥ 18 years.

          6. Non-Metastatic disease in extra-hepatic (are permitted: local lymph nodes &lt; 3 cm,
             less than 5 lung nodes &lt; 11 mm).

          7. Creatinine clearance (calculated with Cockcroft and Gault formula) ≥ 55 ml/min,
             polymorphonuclear neutrophils ≥ 1500 G/L, platelets ≥ 80 G/L, prothrombin ≥ 40% (INR
             ≤ 2.3), serum albumin ≥ 28 g/l, serum bilirubin ≤ 3 x LSN.

          8. Pregnancy test: negative for women of childbearing potential.

          9. Reliable contraception for a childbearing couple, men and woman must have an reliable
             contraception during the treatment and until 6 months following the end of the
             treatment by chemotherapy

         10. Signed informed consent form.

         11. Patient with national health insurance.

        Exclusion Criteria:

          1. Pancreas cancer or duodenum cancer invading the bile duct or ampullary cancer.
             Cholangiocarcinoma of the bile ducts: hilar, main duct, gallbladder.

          2. Extra-hepatic metastasis (including local lymph nodes measuring &gt; 30 mm).

          3. Primary sclerosing cholangitis.

          4. History of chemoembolization or radioembolization.

          5. Cirrhose CHILD &gt; B7

          6. Portal vein trunk tumoral thrombosis

          7. History of hepato-biliary neo adjuvant or palliative chemotherapy and/or
             radiotherapy.

          8. Contra indication of Gemcitabine and/or Cisplatin.

          9. Other invasive active cancer, excepting in situ cervical cancer and basocellular or
             spino cellular skin cancer treated adequately. Any history of cancer not considered
             as completely cured for at least one year.

         10. Technical failure of the diagnostic arteriography.

         11. Extra hepatic uptake on the pre-therapeutic scintigraphy not manageable with an
             arteriography.

         12. Dosimetry study predicting lung exposure &gt; 30 Gy.

         13. Any unstable medical history (diabetes, hypertension …).

         14. History of organ transplant.

         15. Symptomatic grade 1 angina pectoris or grade ≥ 2 angina pectoris.

         16. An evolutive neuropathy.

         17. Patient who already has been involved in a clinical trial with drug intake, whether
             this drug was experimental or not, within 30 days before.

         18. Pregnant patient or patient with breastfeeding.

         19. Patient under administrative supervision.

         20. Regular follow-up impossible for various reasons (psychological, familial,
             economical, and social).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eveline Boucher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugene Marquis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eveline Boucher, MD</last_name>
    <phone>+33(0)299253180</phone>
    <email>e.boucher@rennes.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Beaujon - Service de Chirurgie</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Frages, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Farges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Compagnon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Compagnon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric ASSENAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric ASSENAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Chone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence Chone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU- Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Kreaber-Brodere, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yann Touchefeu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eveline Boucher, MD</last_name>
      <phone>+33(0)299253180</phone>
      <email>e.boucher@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Eveline Boucher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy - Unité de Gastro-Entérologie</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Malka, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Malka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intra-hepatic Cholangiocarcinoma treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
